Credit Agricole S A Trims Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Credit Agricole S A lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 41.8% in the first quarter, HoldingsChannel reports. The firm owned 42,391 shares of the medical equipment provider’s stock after selling 30,497 shares during the period. Credit Agricole S A’s holdings in Zimmer Biomet were worth $4,798,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. raised its stake in Zimmer Biomet by 0.7% during the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider’s stock valued at $2,609,130,000 after buying an additional 166,763 shares in the last quarter. Northern Trust Corp raised its stake in Zimmer Biomet by 7.6% during the fourth quarter. Northern Trust Corp now owns 2,370,224 shares of the medical equipment provider’s stock valued at $250,367,000 after buying an additional 167,435 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Zimmer Biomet by 251.3% during the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after buying an additional 1,488,918 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Zimmer Biomet by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 2,058,898 shares of the medical equipment provider’s stock valued at $233,009,000 after buying an additional 58,060 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Zimmer Biomet by 8.6% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,767,901 shares of the medical equipment provider’s stock valued at $186,743,000 after buying an additional 140,531 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Sang Yi sold 1,000 shares of the business’s stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company’s stock, valued at $1,940,280. The trade was a 4.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.39% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ZBH. UBS Group upped their price objective on Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research note on Friday, August 8th. Raymond James Financial raised their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Wells Fargo & Company decreased their price target on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Royal Bank Of Canada increased their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Stifel Nicolaus set a $115.00 price target on Zimmer Biomet and gave the company a “buy” rating in a research note on Tuesday, May 6th. Nine analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $111.44.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $107.6270 on Friday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $89.22 and a fifty-two week high of $116.71. The business has a 50-day moving average of $95.52 and a two-hundred day moving average of $99.32. The stock has a market capitalization of $21.32 billion, a P/E ratio of 26.19, a P/E/G ratio of 2.06 and a beta of 0.68. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion during the quarter, compared to analysts’ expectations of $2.06 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were given a $0.24 dividend. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is currently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.